Article
Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes.
The Journal of infectious diseases - 1 Nov 2000
Nardin E H, Oliveira G A, Calvo-Calle J M, Castro Z R, Nussenzweig R S, Schmeckpeper B, Hall B F, Diggs C, Bodison S, Edelman R
Abstract excerpt
A multiple antigen peptide (MAP) malaria vaccine containing minimal Plasmodium falciparum circumsporozoite protein repeat epitopes was assessed for safety and immunogenicity in volunteers of known class II genotypes. The MAP/alum/QS-21 vaccine formulation elicited high levels of parasite-specific antibodies in 10 of 12 volunteers expressing DQB1*0603, DRB1*0401, or DRB1*1101 class II molecules. In contrast,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.